Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIORC phase II trial in recurrent glioblastoma
2019-004053-91Phase 2Unknown
- Sponsor
- University of Leeds
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lomustine, procarbazine and vincristine in glioblastoma (GBM) (2 arms), sponsored by University of Leeds. Primary endpoint: Overall survival rate at 9 months. Status: unknown.
02
Drugs
lomustineprocarbazinevincristine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2019-004053-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004053-91.